Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.
This acquisition is in line with Cipla's strategic imperative to augment the company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.
Strengthens investment in channels of the future to expand patient reach
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)